Kestra Medical Technologies (NASDAQ:KMTS) CFO Vaseem Mahboob Sells 8,817 Shares of Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) CFO Vaseem Mahboob sold 8,817 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $22.61, for a total transaction of $199,352.37. Following the completion of the transaction, the chief financial officer directly owned 99,282 shares of the company’s stock, valued at $2,244,766.02. This represents a 8.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Vaseem Mahboob also recently made the following trade(s):

• On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.80, for a total value of $128,305.80.
• On Thursday, July 30th, Vaseem Mahboob sold 3,980 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.75, for a total transaction of $90,545.00.

Kestra Medical Technologies Stock Up 5.1%

Kestra Medical Technologies stock opened at $23.99 on Tuesday. The firm has a market cap of $1.41 billion, a PE ratio of -9.91 and a beta of 0.58. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41. The firm’s 50 day moving average price is $22.62 and its two-hundred day moving average price is $22.48. Kestra Medical Technologies, Ltd. has a twelve month low of $14.10 and a twelve month high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The company had revenue of $28.64 million for the quarter. On average, research analysts predict that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Kestra Medical Technologies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KMTS. Seven Grand Managers LLC bought a new stake in Kestra Medical Technologies during the fourth quarter valued at about $2,652,000. Eventide Asset Management LLC grew its position in shares of Kestra Medical Technologies by 5.4% in the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock valued at $33,671,000 after purchasing an additional 65,288 shares during the last quarter. Summit Partners Public Asset Management LLC bought a new position in shares of Kestra Medical Technologies in the fourth quarter worth about $9,282,000. UBS Group AG lifted its position in shares of Kestra Medical Technologies by 34.9% during the 4th quarter. UBS Group AG now owns 270,058 shares of the company’s stock worth $7,162,000 after purchasing an additional 69,908 shares during the last quarter. Finally, Jennison Associates LLC boosted its stake in Kestra Medical Technologies by 15.0% during the 4th quarter. Jennison Associates LLC now owns 219,355 shares of the company’s stock valued at $5,817,000 after purchasing an additional 28,573 shares during the period.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Wall Street Zen cut Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a research report on Wednesday, July 15th. BTIG Research raised their price target on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. The Goldman Sachs Group lowered their price target on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Finally, Oppenheimer assumed coverage on Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating on the stock. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $27.83.

Key Kestra Medical Technologies News

Here are the key news stories impacting Kestra Medical Technologies this week:

• Neutral Sentiment: Multiple executives, including CFO Vaseem Mahboob and insiders Brian Daniel Webster, Traci S. Umberger, Alfred J. Ford Jr. and Timothy P. Moran, sold shares between July 30 and August 3. The transactions totaled approximately 103,000 shares and more than $2.3 million at prices near $22.60–$23.92. Each filing states that the sales were made to cover tax-withholding obligations tied to vested equity awards, rather than for discretionary investment purposes. SEC insider transaction filings
• Negative Sentiment: The breadth of the selling—including transactions by the CFO and several other insiders—could weigh on sentiment because it reduces management ownership and creates a perception of insider selling pressure. However, the relatively small percentage reductions in most positions and the disclosed tax-related purpose make the signal less bearish than open-market sales based on an expectation of weaker business performance.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.